
Mesenchymal stem cell therapy for breast cancer: Challenges remaining

Armel Herve Nwabo Kamdje¹, Paul Faustin Seke Etet², Kiven Erique Lukong³

¹Department of Biomedical Sciences, University of Ngaoundere, PO Box 454, Ngaoundere-Cameroon

²Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah, 51452, Al-Qaseem, Saudi Arabia

³Department of Biochemistry College of Medicine Room 4D30.5 Health Sciences Bldg University of Saskatchewan, 107 Wiggins Road Saskatoon, SK. S7N 5E5 Canada

Email address:

kamdjewa@yahoo.fr (A. H. Nwabo. Kamdje), Paul.seke@gmail.com (P. F. Seke Etet), Kiven.lukong@usask.ca (K. E. Lukong)

To cite this article:

Armel Herve Nwabo Kamdje, Paul Faustin Seke Etet, Kiven Erique Lukong. Mesenchymal Stem Cell Therapy for Breast Cancer: Challenges Remaining. *International Journal of Biomedical Science and Engineering*. Special Issue: Cancer Research. Vol. 2, No. 6-1, 2014, pp. 20-24. doi: 10.11648/j.ijbse.s.2014020601.13

Abstract: The treatment of breast cancer, the most common malignancy among women worldwide, remains puzzling partly due to the resistance to therapeutics, which associates with the heterogeneity of case clinical presentations, and limits in the current understanding of the pathogenesis of solid cancers. Notably, it remains unclear: (i) whether breast cancer starts strictly as a local disease before metastasizing to the lymph nodes and distant organs, i.e. if cancer initiating cells are local cells that have undergone epithelial to mesenchymal transition; (ii) or if breast cancer is intrinsically a systemic disease started by malfunctioning circulating mesenchymal stem cells (MSCs) infiltrating the breast stroma to start tumorigenesis. Such limits in our understanding of breast cancer biology have been slowing the development of MSC-based therapies exploiting the ability of these cells to home into tumorigenic sites, kill cancer cells, stop neoangiogenesis, and repair damaged tissues, as well as therapeutic approaches using these cells as vehicle for gene therapy and for delivering anticancer therapeutics, which are potential game changing therapeutic approaches, particularly in currently incurable cancers and intractable cases. Major drawbacks to MSC-based therapy implementation and use in breast cancer are herein briefly discussed.

Keywords: Stem Cells, Breast Cancer, Microenvironment, Signaling Pathways, Therapy, Therapeutic Resistance

1. Background

Breast cancer remains the most common malignancy among women worldwide, despite efforts of medical and scientific communities, partly due to difficulties to convert experimental findings into clinically useful information. The incidence of this malignancy has been increasing, and the number of new cases is expected to double by the year 2020, reaching 20 million approximately, with the annual mortality rising from about 6.6 million currently to more than 10 million [1-3], if more efficient early detection strategies are not implemented and better therapeutic approaches introduced.

Herein, we will briefly summarize and discuss the huge body of recent evidence supporting a tremendous potential for stem cell therapy in breast cancer.

2. Mesenchymal Stem Cells and Cancer

MSCs are multipotent stromal progenitor cells mostly found in the bone marrow, which can differentiate in most cell types of mesodermal cell lineages (but also some non-mesodermal cells), including osteocytes, adipocytes, epithelial cells, myocytes, chondrocytes, neurons, fibroblasts, and myofibroblasts, among others [4, 5]. Interest for MSCs in solid cancer therapy rose from their ability to: (i) to home to sites of tumorigenesis, providing a mean for efficient delivery of anticancer drugs [6-9]; (ii) to suppress local inflammation [10, 11], which bears a potential for suppressing tumor-promoting inflammation, a hallmark of primary tumor microenvironment [12, 13] and relapse [14, 15]; and (iii) to promote damaged tissue repair and regeneration [16-18], without any immunogenicity and toxicity to the host.

MSCs represent a promising platform for cell and gene therapy of incurable cancers [13, 19, 20]. The high tropism of

MSCs to cancers, as well as their ability to engraft, survive, and proliferate in the tumor, makes them ideal vehicle for tumor-selective drug delivery. MSCs migrate to sites of tumorigenesis and have been utilized as efficient cellular vehicle for the targeted delivery of anti-neoplastic therapeutics to both primary tumors and their metastases [21]. Several preclinical studies support the basis for genetically modified MSCs to deliver therapeutics to tumor sites; include in glioma, melanoma, Kaposi's sarcoma, Ewing sarcoma, as well as carcinomas of the colon, ovary, and breast [21-28]. Unfortunately, mechanistic insights in MSC homing to sites of malignant growth are missing.

3. Recent Evidence for MSC Anticancer Role

Numerous reports support a therapeutic potential for MSCs in breast cancer. For instance, adipose tissue-derived MSCs cultured at high density suppressed the growth of MCF-7 human breast cancer cells via an IFN- β -dependent mechanism [29]. Similarly, in a co-culture study of human breast cancer cells and bone marrow-derived MSCs an inhibition of growth of breast cancer cells was observed [30]. Mechanisms explaining such effect included silencing of the oncogenic signaling mediated by truncated neurokinin receptor-1 (NK1R-Tr), the tumorigenesis and metastasis promoting factor SDF-1 α , as well as TGF- β genes. Adipose tissue-derived MSCs also increased chemosensitivity of human breast cancer cells in co-culture [31].

Furthermore, a recent bioluminescence imaging study on a breast cancer xenograft mouse model [using human breast cancer cell line MDA-MB-231 carrying a reporter system encoding a double fusion reporter gene consisting of firefly luciferase (Fluc) and enhanced green fluorescent protein (eGFP)] treated with human umbilical cord-derived MSCs [armed with a triple fusion gene containing the herpes simplex virus truncated thymidine kinase (HSV-ttk), renilla luciferase (Rluc) and red fluorescent protein (RFP)] revealed that MSCs can induce apoptosis in breast cancer cells and suppress angiogenesis. [32]. In an in vivo preclinical model of mammary tumors induced by N-nitroso-N-methylurea (NMU), placenta-derived MSCs migrated towards mammary tumors both in vitro and in vivo, and reduced tumor growth and tumor development [33].

4. MSCs and Cancer Stem Cells

MSCs but also various other stem cell types, such as stem cells isolated from the normal mouse mammary gland and human breast reduction tissues [34], are able to perform epithelial-mesenchymal transition (EMT), a latent embryonic program whose aberrant activation would play a pivotal role in the development of chemoresistant cancer stem cells that support highly aggressive primary breast tumors [31, 35-37] metastases [38, 39]. And relapse [40, 41]. This raises concerns for a potential implication of MSCs in breast cancer

pathogenesis, particularly in the current context where the origin of cancer stem cells remains elusive. Thus, though numerous reports suggest that cancer stem cells derive from epithelial cells that have undergone mesenchymal transition [42-46], there is also evidence that these malignant cells may derive from an expansion of pre-existing stem cell populations expressing EMT-associated markers, including MSCs [34, 47, 48].

Oncogenic signaling pathways, such as Wnt, Hedgehog (Hh) and Notch play important roles in cell proliferation regulations and contribute to the self-renewal of stem cells and/or progenitor cells [49-56] are highly expressed in tumor microenvironment [13, 57], where they play a pivotal role in EMT. These signaling pathways would also confer stemness and chemoresistance to a number of transforming cells, which would then become cancer stem cells (for review see [58-61]). Monoclonal antibody-based therapies targeting these cells have been proposed in order to improve the outcome of anticancer therapy, including targeting cancer stem cell specific markers and/or the oncogenic signaling pathways allowing their maintenance, survival, and proliferation [62].

5. Controversy on Stem Cell Biology and Cancer

A recent in vitro study using breast cancer clinical isolates reported that MSCs provide support to actively dividing cancer cells, and the secretome of MSCs isolated from various tissues included numerous cytokines and chemokines implicated in tumor growth and/or metastasis, such as CCL2, CCL5, IL-6, TGF β , and VEGF [31, 63-66]. Such response of breast cancer cells to MSCs could even be increased by inflammation-associated with breast implants [67]. These observations are in agreement with current stem cell biology understanding, from which it can be anticipated as well that MSCs may also fuel breast tumorigenesis in vivo, if introduced massively to neoplastic sites [68-71]. In addition, cells of rare fibroepithelial breast tumors like malignant breast phyllodes were reported various characteristics of MSCs [72], as well as the ability to transform into rhabdomyosarcoma, liposarcoma and osteosarcoma, raising more concern about the use of MSCs in breast cancer.

Interestingly, a xenograft study using a combination of molecular imaging technologies, showed that it is possible to monitor the therapeutic effects, as well as basic molecular and cellular processes of MSCs in real time, but also to better guide MSC mediated cancer therapy, notably using combination therapies with classical chemotherapy drugs [32]. This approach represents a good strategy for preventing potential tumorigenic MSC activities in anticancer therapeutic approaches using these cells. The necessity of monitoring and guiding MSC mediated cancer therapy emerged from another imaging study (using fluorescence), where MSCs promoted mammary tumorigenesis by generation of a cancer-enhancing microenvironment [73],

and various *in vitro* studies with comparable results, including those discussed in the precedent paragraph. Another strategy for preventing MSCs carcinogenic effect emerged from a report suggesting that TGF- β signaling targeting in MSCs abolishes their pro-tumor effects, partly by preventing their transformation in highly pathogenic carcinoma-associated fibroblasts (CAFs), without affecting their stemness and other positive properties, including their tumor-tropic property [74]. Preactivation of human MSCs with TNF- α was also reported as a strategy for biasing MSCs towards tumor-suppressive profile [75]. In this study, weekly infusions into mice of TNF- α preactivated MSCs decreased the progression of lung tumors formed from MDA-MB-231 breast cancer cells.

6. Concluding Remarks and Perspectives

Breast cancer treatment is currently puzzling due to chemoresistance, particularly in some subtypes (like triple negative cancers) and in advanced (metastatic) stages. MSCs bear a high potential in breast cancer therapy, as they constitute a good vehicle for specific delivery of anticancer therapeutics to tumor sites and have tissue repair abilities. Corroborating the huge body of early experimental evidence, emerging clinical evidence also suggests that the use of MSC therapy in breast cancer could be a game changing therapeutic approach. However, it is unclear whether cancer stem cell originate from MSCs. In this case, MSCs may play a pivotal role in cancer tumorigenesis, and thus, strategies increasing their infiltration to breast would fuel tumorigenic processes. Future studies investigating the roles of MSCs in breast tumorigenesis and metastasis formation are necessary, considering the potential of MSCs for breast cancer treatment.




Figure 1. Graphical abstract of the review

References

- [1] Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. *Int.J.Cancer* 2001; 94:153-156
- [2] Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. *Cancer Biol.Ther.* 2007; 6:308-312
- [3] Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J.Clin.Invest* 2011; 121:2750-2767
- [4] Liu ZJ, Zhuge Y, Velazquez OC. Trafficking and differentiation of mesenchymal stem cells. *J.Cell Biochem.* 2009; 106:984-991
- [5] Duenas F, Becerra V, Cortes Y, Vidal S, Saenz L, Palomino J, De Los RM, Peralta OA. Hepatogenic and neurogenic differentiation of bone marrow mesenchymal stem cells from abattoir-derived bovine fetuses. *BMC.Vet.Res.* 2014; 10:154
- [6] Galderisi U, Giordano A, Paggi MG. The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents. *World J.Stem Cells* 2010; 2:5-12
- [7] Bhattacharya A. Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. *Expert.Opin.Drug Deliv.* 2011; 8:749-763
- [8] Pascucci L, Cocce V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, Viganò L, Locatelli A, Sisto F, Doglia SM, Parati E, Bernardo ME, Muraca M, Alessandri G, Bondiolotti G, Pessina A. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit *in vitro* tumor growth: A new approach for drug delivery. *J.Control Release* 2014; 192:262-270
- [9] Lim ML, Ooi BN, Jungebluth P, Sjoqvist S, Hultman I, Lemon G, Gustafsson Y, Asmundsson J, Baiguera S, Douagi I, Gilevich I, Popova A, Haag JC, Rodriguez AB, Lim J, Liedén A, Nordenskjöld M, Alici E, Baker D, Unger C, Luedde T, Vassiliev I, Inzunza J, Ahrlund-Richter L, Macchiarini P. Characterization of stem-like cells in mucoepidermoid tracheal paediatric tumor. *PLoS.One.* 2014; 9:e107712
- [10] El-Jawhari JJ, El-Sherbiny YM, Jones EA, McGonagle D. Mesenchymal stem cells, autoimmunity and rheumatoid arthritis. *QJM.* 2014; 107:505-514
- [11] Eseonu OI, De BC. Homing of mesenchymal stem cells: mechanistic or stochastic? Implications for targeted delivery in arthritis. *Rheumatology.(Oxford)* 2014;
- [12] Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. *Cancer Lett.* 2008; 267:271-285
- [13] Nwabo Kamdje AH, Seke Etet PF, Vecchio L, Muller JM, Krampera M, Lukong KE. Signaling pathways in breast cancer: Therapeutic targeting of the microenvironment. *Cell Signal.* 2014; 26:2843-2856
- [14] Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. Immune-induced epithelial to mesenchymal transition *in vivo* generates breast cancer stem cells. *Cancer Res.* 2009; 69:2887-2895
- [15] Payne KK, Manjili MH. Adaptive immune responses associated with breast cancer relapse. *Arch.Immunol.Ther.Exp.(Warsz.)* 2012; 60:345-350
- [16] Hanson S, D'Souza RN, Hematti P. Biomaterial-mesenchymal stem cell constructs for immunomodulation in composite tissue engineering. *Tissue Eng Part A* 2014; 20:2162-2168
- [17] Clover AJ, Kumar AH, Isakson M, Whelan D, Stocca A, Gleeson BM, Caplice NM. Allogeneic mesenchymal stem cells, but not culture modified monocytes, improve burn wound healing. *Burns* 2014;

- [18] Linero I, Chaparro O. Paracrine effect of mesenchymal stem cells derived from human adipose tissue in bone regeneration. *PLoS.One.* 2014; 9:e107001
- [19] Ozawa K, Sato K, Oh I, Ozaki K, Uchibori R, Obara Y, Kikuchi Y, Ito T, Okada T, Urabe M, Mizukami H, Kume A. Cell and gene therapy using mesenchymal stem cells (MSCs). *J.Autoimmun.* 2008; 30:121-127
- [20] Seke Etet PF, Nwabo Kamdje AH, Mbo Amvene J, Aldebasi Y, Farahna M, Vecchio L. Stromal control of chronic lymphocytic leukemia cells. *Research & Reports in Biology* 2013; 4:23-32
- [21] El-Haibi CP, Karnoub AE. Mesenchymal stem cells in the pathogenesis and therapy of breast cancer. *J.Mammary.Gland.Biol.Neoplasia.* 2010; 15:399-409
- [22] Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. *J.Natl.Cancer Inst.* 2004; 96:1593-1603
- [23] Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. *Cancer Res.* 2005; 65:3307-3318
- [24] Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. *Mol.Cancer Ther.* 2006; 5:755-766
- [25] Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M, Marini FC. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. *Cancer Res.* 2007; 67:11687-11695
- [26] Menon LG, Picinich S, Koneru R, Gao H, Lin SY, Koneru M, Mayer-Kuckuk P, Glod J, Banerjee D. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. *Stem Cells* 2007; 25:520-528
- [27] Coffelt SB, Marini FC, Watson K, Zvezdaryk KJ, Dembinski JL, LaMarca HL, Tomchuck SL, Honer zu BK, Danka ES, Henkle SL, Scandurro AB. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. *Proc.Natl.Acad.Sci.U.S.A* 2009; 106:3806-3811
- [28] Duan X, Guan H, Cao Y, Kleinerman ES. Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. *Cancer* 2009; 115:13-22
- [29] Ryu H, Oh JE, Rhee KJ, Baik SK, Kim J, Kang SJ, Sohn JH, Choi E, Shin HC, Kim YM, Kim HS, Bae KS, Eom YW. Adipose tissue-derived mesenchymal stem cells cultured at high density express IFN-beta and suppress the growth of MCF-7 human breast cancer cells. *Cancer Lett.* 2014; 352:220-227
- [30] Zhou Y, Zuo D, Wang M, Zhang Y, Yu M, Yang J, Yao Z. Effect of truncated neurokinin-1 receptor expression changes on the interaction between human breast cancer and bone marrow-derived mesenchymal stem cells. *Genes Cells* 2014; 19:676-691
- [31] Kucerova L, Skolekova S, Matuskova M, Bohac M, Kozovska Z. Altered features and increased chemosensitivity of human breast cancer cells mediated by adipose tissue-derived mesenchymal stromal cells. *BMC.Cancer* 2013; 13:535
- [32] Leng L, Wang Y, He N, Wang D, Zhao Q, Feng G, Su W, Xu Y, Han Z, Kong D, Cheng Z, Xiang R, Li Z. Molecular imaging for assessment of mesenchymal stem cells mediated breast cancer therapy. *Biomaterials* 2014; 35:5162-5170
- [33] Vegh I, Grau M, Gracia M, Grande J, de la Torre P, Flores AI. Decidua mesenchymal stem cells migrated toward mammary tumors in vitro and in vivo affecting tumor growth and tumor development. *Cancer Gene Ther.* 2013; 20:8-16
- [34] May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. *Breast Cancer Res.* 2011; 13:202
- [35] Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. *PLoS.One.* 2009; 4:e4992
- [36] El-Haibi CP, Bell GW, Zhang J, Collmann AY, Wood D, Scherber CM, Csizmadia E, Mariani O, Zhu C, Campagne A, Toner M, Bhatia SN, Irimia D, Vincent-Salomon A, Karnoub AE. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. *Proc.Natl.Acad.Sci.U.S.A* 2012; 109:17460-17465
- [37] Rappa G, Mercapide J, Lorico A. Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity. *Am.J.Pathol.* 2012; 180:2504-2515
- [38] Jain P, Alahari SK. Breast cancer stem cells: a new challenge for breast cancer treatment. *Front Biosci.(Landmark.Ed)* 2011; 16:1824-1832
- [39] Ito Y, Iwase T, Hatake K. Eradication of breast cancer cells in patients with distant metastasis: the finishing touches? *Breast Cancer* 2012; 19:206-211
- [40] Yu Y, Ramena G, Elble RC. The role of cancer stem cells in relapse of solid tumors. *Front Biosci.(Elite.Ed)* 2012; 4:1528-1541
- [41] Malik B, Nie D. Cancer stem cells and resistance to chemo and radio therapy. *Front Biosci.(Elite.Ed)* 2012; 4:2142-2149
- [42] Biddle A, Gammon L, Fazil B, Mackenzie IC. CD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition. *PLoS.One.* 2013; 8:e57314
- [43] Feng YX, Sokol ES, Del Vecchio CA, Sanduja S, Claessen JH, Proia TA, Jin DX, Reinhardt F, Ploegh HL, Wang Q, Gupta PB. Epithelial-to-mesenchymal transition activates PERK-eIF2alpha and sensitizes cells to endoplasmic reticulum stress. *Cancer Discov.* 2014; 4:702-715
- [44] Guo W. Concise review: breast cancer stem cells: regulatory networks, stem cell niches, and disease relevance. *Stem Cells Transl.Med.* 2014; 3:942-948

- [45] Ferrand N, Gnanaprasadam A, Dorothee G, Redeuilh G, Larsen AK, Sabbah M. Loss of WISP2/CCN5 in estrogen-dependent MCF7 human breast cancer cells promotes a stem-like cell phenotype. *PLoS.One.* 2014; 9:e87878
- [46] Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang Q, Lin Y, Li J, Kang T, Tao M, Rusinova E, Zhang G, Wang C, Zhu H, Yao J, Zeng YX, Evers BM, Zhou MM, Zhou BP. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. *Cancer Cell* 2014; 25:210-225
- [47] Wang KH, Kao AP, Chang CC, Lin TC, Kuo TC. Bisphenol A at environmentally relevant doses induces cyclooxygenase-2 expression and promotes invasion of human mesenchymal stem cells derived from uterine myoma tissue. *Taiwan.J.Obstet.Gynecol.* 2013; 52:246-252
- [48] Rameshwar P. Would cancer stem cells affect the future investment in stem cell therapy. *World J.Exp.Med.* 2012; 2:26-29
- [49] Austin J, Kimble J. glp-1 is required in the germ line for regulation of the decision between mitosis and meiosis in *C. elegans*. *Cell* 1987; 51:589-599
- [50] Henrique D, Hirsinger E, Adam J, Le R, I, Pourquie O, Ish-Horowicz D, Lewis J. Maintenance of neuroepithelial progenitor cells by Delta-Notch signalling in the embryonic chick retina. *Curr.Biol.* 1997; 7:661-670
- [51] Chan EF, Gat U, McNiff JM, Fuchs E. A common human skin tumour is caused by activating mutations in beta-catenin. *Nat.Genet.* 1999; 21:410-413
- [52] Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. *Neuron* 1999; 22:103-114
- [53] Zhu AJ, Watt FM. beta-catenin signalling modulates proliferative potential of human epidermal keratinocytes independently of intercellular adhesion. *Development* 1999; 126:2285-2298
- [54] Polakis P. Wnt signaling and cancer. *Genes Dev.* 2000; 14:1837-1851
- [55] Zhang Y, Kalderon D. Hedgehog acts as a somatic stem cell factor in the *Drosophila* ovary. *Nature* 2001; 410:599-604
- [56] Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. *Proc.Natl.Acad.Sci.U.S.A* 2003; 100:3983-3988
- [57] Chirgwin JM. The stem cell niche as a pharmaceutical target for prevention of skeletal metastases. *Anticancer Agents Med.Chem.* 2012; 12:187-193
- [58] Arend RC, Londono-Joshi AI, Straughn JM, Jr., Buchsbaum DJ. The Wnt/beta-catenin pathway in ovarian cancer: a review. *Gynecol.Oncol.* 2013; 131:772-779
- [59] Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. *Sci.Signal.* 2014; 7:re8
- [60] Klauzinska M, Castro NP, Rangel MC, Spike BT, Gray PC, Bertolette D, Cuttitta F, Salomon D. The multifaceted role of the embryonic gene *Cripto-1* in cancer, stem cells and epithelial-mesenchymal transition. *Semin.Cancer Biol.* 2014;
- [61] Fazilaty H, Mehdipour P. Genetics of breast cancer bone metastasis: a sequential multistep pattern. *Clin.Exp.Metastasis* 2014; 31:595-612
- [62] Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? *MAbs.* 2009; 1:12-25
- [63] Zimmerlin L, Park TS, Zambidis ET, Donnenberg VS, Donnenberg AD. Mesenchymal stem cell secretome and regenerative therapy after cancer. *Biochimie* 2013; 95:2235-2245
- [64] Chung SS, Giehl N, Wu Y, Vadgama JV. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. *Int.J.Oncol.* 2014; 44:403-411
- [65] Zhang T, Lee YW, Rui YF, Cheng TY, Jiang XH, Li G. Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. *Stem Cell Res.Thor.* 2013; 4:70
- [66] Kuo CH, Liu CJ, Lu CY, Hu HM, Kuo FC, Liou YS, Yang YC, Hsieh MC, Lee OK, Wu DC, Wang SS, Chen YL. 17beta-estradiol inhibits mesenchymal stem cells-induced human AGS gastric cancer cell mobility via suppression of. *Int.J.Med.Sci.* 2014; 11:7-16
- [67] Orciani M, Lazzarini R, Scartozzi M, Bolletta E, Mattioli-Belmonte M, Scalise A, Di BG, Di PR. The response of breast cancer cells to mesenchymal stem cells: a possible role of inflammation by breast implants. *Plast.Reconstr.Surg.* 2013; 132:899e-910e
- [68] Pearl RA, Leedham SJ, Pacifico MD. The safety of autologous fat transfer in breast cancer: lessons from stem cell biology. *J.Plast.Reconstr.Aesthet.Surg.* 2012; 65:283-288
- [69] Smalley M, Piggott L, Clarkson R. Breast cancer stem cells: obstacles to therapy. *Cancer Lett.* 2013; 338:57-62
- [70] Krumboeck A, Giovanoli P, Plock JA. Fat grafting and stem cell enhanced fat grafting to the breast under oncological aspects--recommendations for patient selection. *Breast* 2013; 22:579-584
- [71] Bibber B, Sinha G, Lobba AR, Greco SJ, Rameshwar P. A review of stem cell translation and potential confounds by cancer stem cells. *Stem Cells Int.* 2013; 2013:241048
- [72] Lin JJ, Huang CS, Yu J, Liao GS, Lien HC, Hung JT, Lin RJ, Chou FP, Yeh KT, Yu AL. Malignant phyllodes tumors display mesenchymal stem cell features and aldehyde dehydrogenase/disialoganglioside identify their tumor stem cells. *Breast Cancer Res.* 2014; 16:R29
- [73] Ke CC, Liu RS, Suetsugu A, Kimura H, Ho JH, Lee OK, Hoffman RM. In vivo fluorescence imaging reveals the promotion of mammary tumorigenesis by mesenchymal stromal cells. *PLoS.One.* 2013; 8:e69658
- [74] Shangguan L, Ti X, Krause U, Hai B, Zhao Y, Yang Z, Liu F. Inhibition of TGF-beta/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects. *Stem Cells* 2012; 30:2810-2819
- [75] Lee RH, Yoon N, Reneau JC, Prockop DJ. Preactivation of human MSCs with TNF-alpha enhances tumor-suppressive activity. *Cell Stem Cell* 2012; 11:825-835